Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2017

Open Access 01-12-2017 | Research article

Predictors of health care drop-out in an inception cohort of patients with early onset rheumatoid arthritis

Authors: Irazú Contreras-Yáñez, Virginia Pascual-Ramos

Published in: BMC Musculoskeletal Disorders | Issue 1/2017

Login to get access

Abstract

Background

RA patients who eventually dropped out of treatment and out of the health care system had potentially disastrous consequences for their health-related quality-of-life outcomes. Objectives of the study were to identify predictors of health care drop out (HDO) in an inception and ongoing cohort of patients with recent onset RA.

Methods

Charts from patients attending an early arthritis clinic from February 2004 to December 2015, and standardized follow-up evaluations were reviewed. Patients with HDO (cases) were defined when they did not return back to the clinic for a schedule visit for at least one year. Persistence with therapy was defined as length of time patients complied with RA-treatment. A case-control nested within a cohort design was used to compare baseline and cumulative (up to HDO or equivalent follow-up) variables between cases and paired controls (patients compliant with scheduled visits). Cox regression analysis was used to investigate predictors of HDO. The study was approved by the Institutional Review Board and patients gave written informed consent to have their data published.

Results

Data from 170 patients (89.4% female, [mean±SD] age: 38.2±12.6 years) with ≥1 year of follow-up were analyzed; up to December 2015, (median, interquartile rage) follow-up was 86.6 months (43.2–123) during which 35 (20.6%) patients had HDO after 41.1 months (12.1–58.7). Baseline and cumulative variables related to disease activity, treatment and persistence with therapy entered regression models; cumulative number of flares, number of disease-modifying anti-rheumatic drugs /patient and persistence <50% emerged as predictors of HDO. Five cases returned back after (median, range) drop out time of 3.8 years (2.3–5.8); they exhibited higher disability and poorer function than paired controls and outcomes were sustained up to their last follow-up.

Conclusions

In a real clinical setting of an EAC, failure to control disease activity, intensive treatment and poor persistence with therapy predicted HDO. Abandonment of health care had a negative impact on patient outcomes and was sustained even after health care was reinitiated.
Literature
1.
Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE Jr, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care. 2002;8:231–40.PubMed
2.
Sanderson T, Kirwan J. Patient-reported outcomes of arthritis: time to focus on personal life impact measures? Editorial Arthritis Rheum. 2009;61:1–3.PubMed
3.
Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37:481–94.CrossRefPubMed
4.
Mody GM, Cardiel MH. Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Res Clin Rheumatol. 2008;22:621–41.CrossRefPubMed
5.
Pascual-Ramos V, Contreras-Yáñez I, Villa AR, Cabiedes J, Rull-Gabayet M. Medication persistence over two years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and disability. Arthritis Res Ther. 2009;11(1):R26.CrossRefPubMedPubMedCentral
6.
de Klerk E, van der Heijde D, Landewé R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia Rheumatica, and gout. J Rheumatol. 2003;30:44–54.PubMed
7.
Gossec L, Tubach F, Dougados M, Ravaud P. Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. Am J Med Sci. 2007;334:248–54.CrossRefPubMed
8.
Deyo RA, Inui TS, Sullivan B. Noncompliance with arthritis drugs: magnitude, correlates, and clinical implications. J Rheumatol. 1981;8:931–6.PubMed
9.
Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int. 2007;27:743–6.CrossRefPubMed
10.
García-González A, Richardson M, García Popa-Lisseanu M, Cox V, Kallen MA, Janssen N, et al. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2008;27:883–9.CrossRefPubMed
11.
Lorish CD, Richards B, Brown S. Missed medication doses in rheumatic arthritis patients: intentional and unintentional reasons. Arthritis Care Res. 1989;2:3–9.CrossRefPubMed
12.
Lorish CD, Richards B, Brown S. Perspective of the patient with rheumatoid arthritis on issues related to missed medication. Arthritis Care Res. 1990;3:78–84.PubMed
13.
Viller F, Guillemin F, Briançon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol. 1999;26:2114–22.PubMed
14.
Viller F, Guillemin F, Briançon S, Moum T, Suurmeijer T, van den Heuvel W. Compliance with drug therapy in rheumatoid arthritis. A longitudinal European study. Joint Bone Spine. 2000;67:178–82.PubMed
15.
Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR. Assessment of adherence to and persistence on disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care. 2007;45(10 Supl 2):S66–76.CrossRefPubMed
16.
Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patients out-of-pocket payments matter? Arthritis Care Res. 2008;59:1519–26.CrossRef
17.
Contreras-Yáñez I, Ponce de León S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease modifying antirheumatic drugs. Am J Med Sc. 2010;340(4):282–90.CrossRef
18.
Contreras-Yáñez I, Cabiedes J, Villa AR, Rull-Gabayet M, Pascual-Ramos V. Persistence on therapy is a major determinant of patient-, physician- and laboratory- reported outcomes in recent-onset rheumatoid arthritis patients. Clin Exp Rheumatol. 2010;28:748–51.PubMed
19.
Pascual-Ramos V, Contreras-Yáñez I. Motivations for inadequate persistence with disease modifying antirheumatic drugs. The patient’s perspective. BMC Musculoskelet Disord. 2013;14:336.CrossRefPubMedPubMedCentral
20.
Lim TO, Ngah BA. The Mentakab hypertension study project. Part II- why do hypertensives drop out of treatment? Singap Med J. 1991;32:249–51.
21.
Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van riel PL. modified disease activity score that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.CrossRefPubMed
22.
Contreras-Yáñez I, Pascual-Ramos V. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters. Arthritis Res Ther. 2015;17:177.CrossRefPubMedPubMedCentral
23.
van Gestel AM, Prevoo ML, van’t Hof MA, van Rijswijk MH, van de Putte LB, van riel PL. development and validation of the European league against rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/international league against rheumatism criteria. Arthritis Rheum. 1996;39:34–40.CrossRefPubMed
24.
Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis. 2002;61:290–7.CrossRefPubMedPubMedCentral
25.
Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66:34–45.CrossRefPubMed
26.
Nell-Duxneuner V, Rezende LS, Stamm TA, Duer M, Smolen JS, Machold KP. Attending and non-attending patients in a real-life setting on an early arthritis clinic: why do people leave clinics and where do they go? Clin Exp Rheumatol. 2012;30:184–90.PubMed
27.
Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol Suppl. 2004;69:14–21.PubMed
28.
Welsing PM, Fransen J, van Riel PL. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum. 2005;52:2616–24.CrossRefPubMed
29.
van Aken J, Lard LR, le Cessie S, Hazes JM, Breedveld FC, Huizinga TW. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann Rheum Dis. 2004;63:274–9.CrossRefPubMedPubMedCentral
30.
Markusse IM, Dirven L, Han KH, Ronday HK, Kerstens PJ, Lems WF, et al. Continued participation in a ten-year tight control treat-to-target study in rheumatoid arthritis: why keep patients doing their best? Arthritis Car Res. 2015;67:739–45.CrossRef
31.
Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Jarvenpaa S, Leirisalo-Repo M, et al. The good initial response to therapy with the combination of traditional disease modifying anti-rheumatic drugs is sustained over time: the eleven-year results of the Finnish Rheumatoid Arthritis Combination Therapy Trial. Arthritis Rheum. 2009;60:1222–31.CrossRefPubMed
32.
van Tuyl LH, Boers M, Lems WF, Landewé RB, Han H, van der Linden S, et al. Survival, comorbidities, and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis. 2010;69:807–12.CrossRefPubMed
33.
Reisine S, Fifield J, Winkelman DK. Characteristics of rheumatoid arthritis patients: who participates in long-term research and who drops out? Arthritis Car Res. 2000;13:3–10.CrossRef
34.
Udrea G, Dumitrescu B, Purcarea M, Balan I, Rezus E, Deculescu D, et al. Patient’s perspectives and motivators to participate in clinical trials with novel therapies for rheumatoid arthritis. J Med Life. 2009;2:227–31.PubMedPubMedCentral
35.
van der Helm-van Mil AH, le Cessie S, van Dongen H, Breedveld FC, Toes RE, Huizinga TW. A prediction rule for disease outcome in patientes with recent-onset undifferentiatied arthritis: how to guide individual treatment decisions. Arthritis Rheum. 2007;56:433–40.CrossRefPubMed
36.
de Vries-Bouwstra J, Le Cessie S, Allaart C, Breedveld F, Huizinga T. Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis. J Rheumatol. 2006;33(9):1747–53.PubMed
37.
Harrison BJ, Symmons DP, Brenan P, Barret EM, Silman AJ. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol. 1996;35:1096–100.CrossRefPubMed
38.
Strangfeld A, Zink A. Comparison of treatment, and outcome of rheumatological and non-rheumatological care in patients with rheumatoid arthritis. Rheumatology. 2005;44(Suppl. 1):i74.
39.
Wong M, Mulherin D. The influence of medication beliefs and other psychosocial factors on early discontinuation of disease-modifying anti-rheumatic drugs. Musculoskeletal Car. 2007;(5):148–59.
40.
Rossi A, Amaddeo F, Bisoffi G, Ruggeri M, Thornicroft G, Tansella M. Dropping out of care: inappropriate terminations of contact with community-based psychiatric services. Br J Psych. 2002;181:331–8.CrossRef
Metadata
Title
Predictors of health care drop-out in an inception cohort of patients with early onset rheumatoid arthritis
Authors
Irazú Contreras-Yáñez
Virginia Pascual-Ramos
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2017
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-017-1670-6

Other articles of this Issue 1/2017

BMC Musculoskeletal Disorders 1/2017 Go to the issue

Research article

Accuracy of clinical neurological examination in diagnosing lumbo-sacral radiculopathy: a systematic literature review

Research article

Assessment of success of the Ponseti method of clubfoot management in sub-Saharan Africa: a systematic review

Research article

A new multiple trauma model of the mouse

Research article

Percutaneous medial hemi-epiphysiodesis using a transphyseal screw for caput valgum associated with developmental dysplasia of the hip

Research article

Associated factors with functional disability and health-related quality of life in Chinese patients with gout: a case-control study

Research article

Effect of low-magnitude different-frequency whole-body vibration on subchondral trabecular bone microarchitecture, cartilage degradation, bone/cartilage turnover, and joint pain in rabbits with knee osteoarthritis